A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
BUSINESS
DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
Dainippon Sumitomo Pharma’s (DSP) sales during the April-September period climbed 1.5% from the same period last year to 181,396 million yen, helped by increased sales in North America of its atypical antipsychotic drug Latuda (lurasidone HCl). However, DSP said its…
To read the full story
BUSINESS
- Nipro, Nichi-Iko to Consolidate Injectable Antibiotics Production by 2026
November 7, 2025
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Genmab Seeks Label Expansion for Epkinly Combo Use in Japan
November 7, 2025
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
- Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…